Виявлено ключові детермінанти розбудови фармацевтики Німеччини, показано роль держави в нарощуванні ендогенних інноваційних ресурсів галузі, посиленні конкуренції та завоюванні зовнішніх ринків. Обґрунтовано необхідність запровадження механізмів зменшення залежності від імпортних компонентів та інноваційного розвитку фармацевтики України, а також преференцій при публічних закупівлях вітчизняних лікарських засобів та медичних виробів.

The evolution of the development of the German chemical and pharmaceutical industry from technology borrowing to endogenous innovations and becoming a global leader is shown. It is substantiated that the government of the country promoted the development of a new industry by increasing budget allocations for the training of scientifi c and industrial personnel; research subsidies; subsidies for transportation and raw materials. It is shown that the formation of large companies has provided economies of scale and accelerated development. Th e creation of specialized research institutes under the auspices of the government initiated public-private partnerships in research funding, industry associations helped mobilize the public to support the industry, and competent company managers and industry representatives together with prominent statesmen provided concerted action to strengthen its innovation potential. Cultivating the national consciousness that the purchase of German goods is the key to the welfare of the state has determined consumer preferences and has become a powerful stimulus to expand supplies to the domestic market. Th e introduction of high customs tariff s on fi nished medicines has provided protection for the new industry in its infancy. Th e close cooperation of banks with pharmaceutical companies has contributed to the implementation of investment and innovation projects and external expansion. Th e creation of cartels by chemical and pharmaceutical companies was an institutional response to the unprecedented phenomenon of industrialization and catching up in Germany. It is revealed that at the present stage the Government of Germany through national and regional programs continues to promote the development of technological and innovative potential of pharmaceuticals. Th e expediency of introduction of mechanisms of endogenization of production development of medicines and medical devices in Ukraine, and also expansion of sales in the domestic market through introduction of preferences at public purchases in the context of protection of essential interests of safety and health of the nation is proved.